FrancophonIA/ELRC3.0 huggingface dataset:
English: EU/1/01/197/003 (1 ml) EU/1/01/197/004 (3 ml) EU/1/01/197/005 (6 ml)
Slovenian: EU/1/01/197/005 (6 ml)
English: Foscan must not be diluted with aqueous solutions.
Slovenian: Zdravila Foscan ne redčite z vodnimi raztopinami.
English: • Foscan will make you sensitive to light for about 15 days after your injection.
Slovenian: • Po injiciranju zdravila Foscan boste preobčutljivi za svetlobo za približno 15 dni.
English: The patency of the in-dwelling cannula should be tested before injection.
Slovenian: Pred injiciranjem je treba preizkusiti prehodnost notranje kanile.
English: How to store Foscan
Slovenian: Shranjevanje zdravila Foscan
English: • You may get constipation.
Slovenian: • Lahko postanete zaprti.
English: 1 mg/1 ml 3 mg/3 ml 6 mg/6 ml
Slovenian: 3 mg/3 ml
English: The required dose of Foscan is administered by slow intravenous injection, over not less than 6 minutes.
Slovenian: Ustrezen odmerek zdravila Foscan aplicirajte s počasnim intravenskim injiciranjem najmanj 6 minut.
English: A skin photosensitivity test must be carried out before the patient returns to normal light conditions.
Slovenian: Preden se bolnik lahko vrne na normalno osvetljenost, mora biti izveden poskus občutljivosti kože za svetlobo.
English: As a precautionary measure, if prolonged outdoor activity is planned, the injection arm should be protected by wearing long sleeved, coloured clothing.
Slovenian: Kot varnostni ukrep v primerih, kadar načrtujete daljšo aktivnost na prostem, zaščitite roko, v katero ste dobili injekcijo, z barvastim oblačilom z dolgimi rokavi.
English: Pain, other than injection site pain, listed in section 4.8 may require the use of NSAIDs or opiate analgesics for a short time following treatment.
Slovenian: Kratek čas po zdravljenju bo morda potrebna uporaba nesteroidnih protivnetnih zdravil ali opiatnih analgetikov zaradi bolečin, poleg bolečine na mestu injiciranja, ki je navedena v poglavju 4.8.
English: - The active substance is temoporfin.
Slovenian: - Zdravilna učinkovina je temoporfin.
English: Temoporfin is a photosensitising agent used in the photodynamic therapy of tumours.
Slovenian: Temoporfin je učinkovina, ki zvečuje občutljivost za svetlobo in se uporablja pri fotodinamičnem zdravljenju tumorjev.
English: • You must avoid becoming pregnant for 3 months after Foscan treatment.
Slovenian: • Do treh mesecev po zdravljenju z zdravilom Foscan ne smete zanositi.
English: Foscan 1 mg/ml solution for injection
Slovenian: Foscan 1 mg/ml raztopina za injiciranje
English: As a precautionary measure, if prolonged outdoor activity is planned, the injection arm should be protected by wearing a long sleeved, coloured shirt.
Slovenian: Kot varnostni ukrep v primerih, kadar načrtujete daljšo aktivnost na prostem, zaščitite mesto injiciranja na roki z barvasto srajco z dolgimi rokavi.
English: • Do not let an optician or ophthalmologist examine your eyes with bright lights for 30 days after Foscan injection.
Slovenian: • 30 dni po injiciranju zdravila Foscan ne smete dovoliti, da vam optik ali oftalmolog pregleda oči z močno svetlobo.
English: 96 hours after the administration of Foscan, the treatment site is to be illuminated with light at 652 nm from an approved laser source.
Slovenian: 96 ur po aplikaciji zdravila Foscan mora biti zdravljeno mesto obsevano s predpisano lasersko svetlobo valovne dolžine 652 nm. Svetloba mora obsijati celotno površino tumorja preko predpisanih optičnih vlaken z mikrolečami.
English: The therapeutic effect is mediated through the generation of highly reactive oxygen species, a process dependent on the intracellular interaction of temoporfin with light and oxygen.
Slovenian: Farmakološka aktivnost se prične s fotoaktivacijo temoporfina, injiciranega v žilo, z lučjo, ki ne oddaja toplote, z valovno dolžino 652 nm. Terapevtski učinek se posreduje z generiranjem visoko reaktivnih kisikovih spojin, procesom, ki je odvisen od znotrajcelične interakcije temoporfina s svetlobo in kisikom.
English: Each ml of solution contains 1 mg of temoporfin.
Slovenian: En mililiter raztopine vsebuje 1 mg temoporfina.
English: Constipation, stomatitis necrotising, dysphagia Common:
Slovenian: Zelo pogosti: obstipacija, nekrotizirajoči stomatitis, disfagija Pogosti: bruhanje, navzea, razjede v ustih
English: Foscan 1 mg/ml solution for injection Temoporfin
Slovenian: Foscan 1 mg/ml raztopina za injiciranje temoporfin
English: Common: Trismus Unknown: Fistula
Slovenian: Neznano: fistula
English: Adverse reactions, including cholangitis, cholecystitis, liver abscess and oesophageal perforation have been reported after unapproved use in the treatment of malignant biliary strictures and mesothelioma.
Slovenian: Po neodobreni uporabi v zdravljenju malignih biliarnih striktur in mezotelioma so poročali o neželenih učinkih, med drugim o holangitisu, holecistitisu, abscesu jeter in perforaciji požiralnika.
English: What Foscan contains
Slovenian: Kaj vsebuje zdravilo Foscan:
English: Do not store above 25
Slovenian: Shranjujte pri temperaturi do 25 ºC.
English: The active substance is temoporfin.
Slovenian: Zdravilna učinkovina je temoporfin.
English: Talk to your doctor for more information.
Slovenian: Če želite o tem več informacij, se posvetujte z zdravnikom.
English: Like all medicines, Foscan can cause side effects.
Slovenian: Možni neželeni učinki Kot vsa zdravila ima lahko tudi zdravilo Focan neželene učinke.
English: Very common:
Slovenian: Zelo pogosti: krvavitev
English: • Do not use UV sunbeds or sunbathe for 3 months after Foscan injection.
Slovenian: • 3 mesece po injiciranju zdravila Foscan ne smete uporabljati UV solarijev ali se sončiti.
English: For 6 months following Foscan treatment, care should be taken to avoid direct prolonged sunlight exposure of the arm used for Foscan injection.
Slovenian: Šest mesecev po zdravljenju z zdravilom Foscan je treba mesto injiciranja zdravila na roki zaščititi pred dolgotrajno neposredno izpostavljenostjo sončni svetlobi.
English: The dark purple colour of the solution together with the amber vial makes a visual check for particulates impossible.
Slovenian: Zaradi temno vijolične barve raztopine in jantarjeve barve viale ni mogoče videti, ali raztopina vsebuje delce.
English: For 3 months following Foscan treatment, avoid UV tanning beds.
Slovenian: 3 mesece po zdravljenju z zdravilom Foscan ne hodite v solarije z UV-svetlobo.
English: Serious side effects such as inflammation of bile duct or gallbladder, liver abscess or perforation in the treated area have been reported when used in other cancer than head and neck.
Slovenian: Pri zdravljenju drugih vrst raka, ne raka glave in vratu, so poročali o resnih neželenih učinkih, na primer o vnetju žolčevoda ali žolčnika, jetrnem abscesu ali perforaciji v zdravljenem predelu.
English: Regarding the tabulated adverse reactions gastrointestinal disorders, adverse skin reactions and general disorders and administration site conditions are the most frequently observed adverse reactions.
Slovenian: Glede na neželene učinke, navedene v preglednici, so bili najpogosteje opaženi neželeni učinki bolezni prebavil, neželeni učinki na koži ter splošne težave in spremembe na mestu aplikacije.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
Slovenian: VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 mg/1 ml
English: For 6 months following Foscan treatment prolonged direct sunlight exposure of the injection site arm shall be avoided.
Slovenian: 6 mesecev po zdravljenju z zdravilom Foscan mesto injiciranja zdravila na roki zaščitite pred dolgotrajno neposredno izpostavljenostjo sončni svetlobi.
English: You can go outdoors after dusk.
Slovenian: Po mraku lahko greste iz hiše.
English: B. PACKAGE LEAFLET
Slovenian: VSEBINA PAKIRANJA
English: To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.The amount of alcohol in this medicinal product may alter the effects of other medicines.The amount of alcohol in this medicinal product may impair the ability to drive or use machines.
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Količina alkohola v tem zdravilu lahko zmanjša sposobnost vožnje ali upravljanja s stroji.
English: • Giddiness
Slovenian: • omotica.
English: • For 6 months following Foscan treatment, avoid prolonged direct sunlight exposure of the injection site arm. As a precautionary measure, if prolonged outdoor activity is planned, protect your injection arm by wearing long sleeved, coloured clothing.
Slovenian: • 6 mesecev po zdravljenju z zdravilom Foscan mesto injiciranja zdravila na roki zaščitite pred dolgotrajno neposredno izpostavljenostjo sončni svetlobi.
English: • Burns
Slovenian: • opekline
English: Please ask your doctor or nurse if you are not sure about anything.
Slovenian: Če niste prepričani glede česarkoli, prosimo, vprašajte svojega zdravnika ali medicinsko sestro.
English: Respiratory, thoracic and mediastinal disorders Unknown: Airway obstruction
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora
English: ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES
Slovenian: PRILOGA I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH
English: Bratislava 811 08
Slovenian: Cintorínska 3/A Bratislava 811 08
English: Roche Oy Klovinpellontie 3 P.O.
Slovenian: Roche Oy Klovinpellontie 3 P.O. Box 12
English: Dukelských hrdinů 567/52, 170 00 Praha 7
Slovenian: Dukelských hrdinů 567/52,
English: G. A. Stamatis & Co. Ltd. 27, Andreas Araouzos P.O.
Slovenian: G. A. Stamatis & Co. Ltd. 27, Andreas Araouzos P.O. Box 21305
English: Belgium N.V. Roche S.A. Rue Dante 75
Slovenian: Roche S.A. Rue Dante 75
English: Slovak Republic Roche Slovensko s.r.o.
Slovenian: Roche Slovensko s.r.o.
English: 3446 GR Woerden
Slovenian: Beneluxlaan 2a 3446 GR Woerden The Netherlands
English: 500 mg Powder for Infusion Intravenous use 50 mg/ml
Slovenian: Prašek za infundiranje Intravenska uporaba 50 mg/ml
English: The Netherlands Roche Nederland B.V. Beneluxlaan 2a
Slovenian: Roche Nederland B.V.
English: 500 mg Lyophilisate for parenteral use (infusion)
Slovenian: Liofilizat za parenteralno uporabo (infuzijo)
English: Roche România SRL Piata Presei Libere , Nr. 3-5, Clădirea City Gate -Turnul de Sud, Etajele 4A, 5 şi 6, Sector 1, Bucureşti
Slovenian: Roche România SRL Piata Presei Libere , Nr. 3
English: The major metabolite NAP226-90 also did not show a genotoxic potential.
Slovenian: Tudi poglavitni presnovek NAP226-90 ni imel genotoksičnega potenciala.
English: 82041 Oberhaching Germany
Slovenian: 82041 Oberhaching
English: If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time
Slovenian: Če predložitev PSUR in posodobitev RMP sovpadata, se lahko predložita sočasno.
English: Hard capsule
Slovenian: Trde kapsule
English: Printing ink:
Slovenian: Črnilo tiska:
English: • Hyperactivity (high level of activity, restlessness) Not known (frequency cannot be estimated from the available data)
Slovenian: • hiperaktivnost (povečana stopnja aktivnosti, nemir) Neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov)
English: A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer's disease (n=75 smokers and 549 nonsmokers) following rivastigmine oral capsule doses of up to 12 mg/day.
Slovenian: Analiza populacijske farmakokinetike je pokazala, da uporaba nikotina poveča očistek po peroralni uporabi za 23 % pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) po uporabi peroralnih kapsul rivastigmina v odmerkih do 12 mg/dan.
English: Date of first authorisation: 11/12/2009 Date of first renewal: 19/08/2014
Slovenian: Datum prve odobritve: 11.12.2009 Datum prvega podaljšanja: 19/08/2014
English: If you have not taken Rivastigmine 1 A Pharma for more than three days, do not take the next dose until you have talked to your doctor.
Slovenian: Če zdravila Rivastigmin 1 A Pharma niste vzeli več kot tri dni, ne vzemite naslednjega odmerka, dokler se ne posvetujete z zdravnikom.
English: Date of first authorization: 11/12/2009 Date of first renewal: 19/08/2014
Slovenian: Datum prve odobritve: 11.12.2009 Datum prvega podaljšanja: 19.08.2014
English: Rivastigmine 1 A Pharma should not be given at the same time as other medicines with similar effects to Rivastigmine 1 A Pharma.
Slovenian: Zdravilo Rivastigmin 1 A Pharma se ne sme uporabiti sočasno z drugimi zdravili, ki imajo podobne učinke kot zdravilo Rivastigmin 1 A Pharma.
English: • Too much saliva and dehydration
Slovenian: • čezmerno slinjenje in dehidracija,
English: Rivastigmine 1 A Pharma might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson's disease or to prevent travel sickness).
Slovenian: Zdravilo Rivastigmin 1 A Pharma bi lahko vplivalo na zdravljenje z antiholinergičnimi zdravili (zdravili, ki se uporabljajo za lajšanje želodčnih krčev ali spazmov, za zdravljenje Parkinsonove bolezni ali za preprečevanje slabosti na potovanju).
English: Do not use Rivastigmine 1 A Pharma after the expiry date which is stated on the carton.
Slovenian: Zdravila Rivastigmin 1 A Pharma ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
English: The European Medicines Agency has waived the obligation to submit the results of studies with rivastigmine in all subsets of the paediatric population in the treatment of Alzheimer's dementia and in the treatment of dementia in patients with idiopathic Parkinson's disease (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom Rivastigmin 1 A Pharma za vse skupine pediatrične populacije glede zdravljenja Alzheimerjeve demence in zdravljenja demence pri bolnikih z idiopatsko Parkinsonovo boleznijo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: • Tell your caregiver that you are taking Rivastigmine 1 A Pharma.
Slovenian: • Povejte svojemu negovalcu, da jemljete zdravilo Rivastigmin 1 A Pharma.
English: By blocking these enzymes, Rivastigmine 1 A Pharma allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's disease and dementia associated with Parkinson's disease.
Slovenian: Zdravilo Rivastigmin 1 A Pharma z blokiranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence, v povezavi s Parkinsonovo boleznijo.
English: However, rivastigmine may be used in this patient population and close monitoring is necessary.
Slovenian: Vendar se zdravilo Rivastigmin 1 A Pharma v tej populaciji bolnikov lahko uporabi in potrebno je natančno spremljanje.
English: If you accidentally take more Rivastigmine 1 A Pharma than you should, inform your doctor.
Slovenian: Če nehote vzamete več zdravila Rivastigmin 1 A Pharma, kot bi smeli, obvestite svojega zdravnika.
English: The PSUR cycle of Rivastigmine 1 A Pharma is aligned with the cross-referred product, Exelon, until otherwise specified.
Slovenian: PSUR cikel za Rivastigmin 1 A Pharma je usklajen s ciklom referenčnega produkta Exelon, razen v primeru spremembe.
English: Red iron oxide (E172)
Slovenian: - rdeči železov oksid (E172)
English: Your doctor will tell you what dose of Rivastigmine 1 A Pharma to take.
Slovenian: Zdravnik vam bo povedal, kakšen odmerek zdravila Rivastigmin 1 A Pharma morate jemati.
English: If you find you have forgotten to take your dose of Rivastigmine 1 A Pharma, wait and take the next dose at the usual time.
Slovenian: Če ste pozabili vzeti zdravilo Rivastigmin 1 A Pharma Če ugotovite, da ste pozabili vzeti odmerek zdravila Rivastigmin 1 A Pharma, počakajte in ob običajnem času vzemite naslednji odmerek.
English: What Rivastigmine 1 A Pharma is and what it is used for
Slovenian: Kaj je zdravilo Rivastigmin 1 A Pharma in za kaj ga uporabljamo
English: If this applies to you, tell your doctor and do not take Rivastigmine 1 A Pharma.
Slovenian: Če kaj od navedenega velja za vas, povejte svojemu zdravniku in ne jemljite zdravila Rivastigmin 1 A
English: • Decreased appetite
Slovenian: • zmanjšan apetit.
English: Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions.
Slovenian: Pri bolnikih s telesno maso manjšo od 50 kg je lahko število neželenih učinkov večje,
English: Rivastigmine 1 A Pharma 1.5 mg hard capsules Rivastigmine 1 A Pharma 3 mg hard capsules Rivastigmine 1 A Pharma 4.5 mg hard capsules Rivastigmine 1 A Pharma 6 mg hard capsules
Slovenian: Rivastigmin 1 A Pharma 1,5 mg trde kapsule Rivastigmin 1 A Pharma 3 mg trde kapsule Rivastigmin 1 A Pharma 4,5 mg trde kapsule Rivastigmin 1 A Pharma 6 mg trde kapsule rivastigmin
English: What Rivastigmine 1 A Pharma is and what it is used for What you need to know before you take Rivastigmine 1 A Pharma How to take Rivastigmine 1 A Pharma Possible side effects
Slovenian: Kaj je zdravilo Rivastigmin 1 A Pharma in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Rivastigmin 1 A Pharma Kako jemati zdravilo Rivastigmin 1 A Pharma
English: - The other ingredients are hypromellose, magnesium stearate, microcrystalline cellulose, colloidal anhydrous silica, gelatin, yellow iron oxide , red iron oxide , titanium dioxide and shellac.
Slovenian: - Pomožne snovi so hipromeloza, magnezijev stearat, mikrokristalna celuloza, koloidni brezvodni silicijev dioksid, želatina, rumeni železov oksid , rdeči železov oksid , titanov dioksid in šelak.
English: Caution when Rivastigmine 1 A Pharma is taken together with beta-blockers (medicines such as atenolol used to treat hypertension, angina and other heart conditions).
Slovenian: Previdnost je potrebna, kadar jemljete zdravilo Rivastigmin 1 A Pharma skupaj z zaviralci receptorjev beta (zdravila, kot so atenolol za zdravljenje hipertenzije, angine pektoris in drugih srčnih bolezni).
English: Rivastigmine 1 A Pharma may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose.
Slovenian: Rivastigmin 1 A Pharma lahko povzroči vrtoglavost in zaspanost, predvsem na začetku zdravljenja ali ob povečanju odmerka.
English: What you need to know before you take Rivastigmine 1 A Pharma Do not take Rivastigmine 1 A Pharma
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Rivastigmin 1 A Pharma Ne jemljite zdravila Rivastigmin 1 A Pharma
English: - if you are allergic to rivastigmine (the active substance of Rivastigmine 1 A Pharma) or any of the other ingredients of this medicine (listed in section 6).
Slovenian: - če ste alergični na rivastigmin (zdravilno učinkovino v zdravilu Rivastigmin 1 A Pharma) ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: If you take more Rivastigmine 1 A Pharma than you should
Slovenian: Če ste vzeli večji odmerek zdravila Rivastigmin 1 A Pharma, kot bi smeli
English: Shellac
Slovenian: - šelak
English: Content of the pack and other information What Rivastigmine 1 A Pharma contains
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Rivastigmin 1 A Pharma
English: The secondary definition of response required a 4--point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS.
Slovenian: Sekundarna opredelitev odziva je zahtevala izboljšanje pri ADAS-Cog za najmanj 4 točke in nobenega poslabšanja pri CIBIC-Plus ter PDS.
English: Rivastigmine 1 A Pharma oral solution is supplied as 50 ml or 120 ml of a clear, yellow solution (2.0 mg/ml base) in an amber glass bottle with a child-resistant cap, foam liner, dip tube and self aligning plug.
Slovenian: Peroralna raztopina Rivastigmin 1 A Pharma je na voljo v obliki 50 ml ali 120 ml bistre rumene raztopine (2 mg/ml baze), v jantarno obarvani steklenici z za otroke varno zaporko, oblogo iz penaste gume, s kapalnim vložkom in s prilegajočim se zamaškom.
English: Uncommon (may affect up to 1 in 100 people) • Uneven heartbeat and poor control of movements
Slovenian: Občasni (pojavijo se pri do 1 bolniku od 100) • nepravilen srčni utrip in motnje koordinacije gibov.
English: Rivastigmine 1 A Pharma should not be given at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting).
Slovenian: Zdravilo Rivastigmin 1 A Pharma se ne sme uporabljati skupaj z metoklopramidom (zdravilo za lajšanje ali preprečevanje slabosti in bruhanja).
English: Important information about some of the ingredients of Rivastigmine 1 A Pharma
Slovenian: Pomembne informacije o nekaterih sestavinah zdravila Rivastigmin 1 A Pharma
English: Use Rivastigmine 1 A Pharma oral solution within 1 month of opening the bottle.
Slovenian: Peroralno raztopino Rivastigmin 1 A Pharma porabite v 1 mesecu po prvem odprtju steklenice.
English: 3 years Rivastigmine 1 A Pharma oral solution should be used within 1 month of opening the bottle.
Slovenian: Peroralno raztopino Rivastigmin 1 A Pharma je treba porabiti v enem mesecu po prvem odprtju steklenice.
English: How to store Rivastigmine 1 A Pharma Contents of the pack and other information
Slovenian: Shranjevanje zdravila Rivastigmin 1 A Pharma Vsebina pakiranja in dodatne informacije
English: • Take Rivastigmine 1 A Pharma twice a day, in the morning and evening, with food.
Slovenian: • Zdravilo Rivastigmin 1 A Pharma jemljite s hrano dvakrat na dan, zjutraj in zvečer.
English: Other medicines and Rivastigmine 1 A Pharma
Slovenian: Druga zdravila in zdravilo Rivastigmin 1 A Pharma
English: The following additional adverse reactions have been observed with rivastigmine transdermal patches: delirium, pyrexia, decreased appetite, urinary incontinence (common), psychomotor hyperactivity (uncommon), erythema, urticaria, vesicles, allergic dermatitis (not known).
Slovenian: Pri uporabi transdermalnih obližev rivastigmina so dodatno opažali še naslednje neželene učinke: delirij, zvišano telesno temperaturo, zmanjšan apetit, urinska inkontinenca (pogosto), psihomotorična hiperaktivnost (občasno), eritem, urtukarija, vezikli, alergijski dermatitis (neznano).
English: The active substance of Rivastigmine 1 A Pharma is rivastigmine.
Slovenian: Zdravilna učinkovina v zdravilu Rivastigmin 1 A Pharma je rivastigmin.
English: If you are pregnant, the benefits of using Rivastigmine 1 A Pharma must be assessed against the possible effects on your unborn child. Rivastigmine 1 A Pharma should not be used during pregnancy unless clearly necessary.
Slovenian: V primeru, da ste noseči, je treba pretehtati koristi uporabe zdravila Rivastigmin 1 A Pharma in možne učinke na nerojenega otroka.
English: Rivastigmine 1 A Pharma 3 mg and 6 mg hard capsules:
Slovenian: Rivastigmin 1 A Pharma 3 mg in 6 mg trde kapsule:
English: If you have to undergo surgery whilst taking Rivastigmine 1 A Pharma, you should tell your doctor before you are given any anaesthetics, because Rivastigmine 1 A Pharma may exaggerate the effects of some muscle relaxants during anaesthesia.
Slovenian: Če morate v času jemanja zdravila Rivastigmin 1 A Pharma na operacijo, povejte zdravniku, da jemljete Rivastigmin 1 A Pharma, preden dobite kakršnokoli anestezijo, ker lahko Rivastigmin 1 A
English: Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by rivastigmine was similar to that of AChE.
Slovenian: v CSF z rivastigminom odvisna od odmerka do največjega preizkušanega odmerka 6 mg, danega dvakrat na dan. Inhibicija aktivnosti butirilholinesteraze v CSF pri 14 bolnikih z Alzheimerjevo boleznijo, zdravljenih z rivastigminom, je bila podobna kot inhibicija AChE.
English: Some people who have accidentally taken too much Rivastigmine 1 A Pharma have experienced feeling sick (nausea),being sick (vomiting), diarrhoea, high blood pressure and hallucinations.
Slovenian: Rivastigmin 1 A Pharma je prišlo do navzee (slabosti s siljenjem na bruhanje), bruhanja, driske, visokega krvnega tlaka in halucinacij.